<DOC>
	<DOCNO>NCT01247805</DOCNO>
	<brief_summary>The hypothesis trial Sildenafil Citrate Powder Oral Suspension ( 10 Mg/ml ) bioequivalent Revatio 20 Mg IR tablet Healthy Volunteers Sildenafil Citrate 10 Mg immediate release ( IR ) tablet bioequivalent Revatio 20 Mg IR tablet Healthy Volunteers .</brief_summary>
	<brief_title>A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension ( 10 Mg/Ml ) And The Sildenafil 10 Mg Immediate Release ( IR ) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 ) Healthy male/female subject age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . 2 . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . 3 . An informed consent document sign date subject legally acceptable representative . 4 . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , ocular allergic ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease clinical finding Screening . 2 . History febrile illness within 5 day prior first dose . 3 . A positive urine drug screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Powder oral suspention</keyword>
</DOC>